We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LENALIDOMIDE SANDOZ (Sandoz Pty Ltd)
Product name
LENALIDOMIDE SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
123 (255 working days)
Active ingredients
lenalidomide
Registration type
New generic medicine
Indication
Multiple Myeloma (MM)
LENALIDOMIDE SANDOZ (capsule) is indicated for the treatment of multiple myeloma.
Myelodysplastic Syndromes (MDS)
LENALIDOMIDE SANDOZ is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Mantle Cell Lymphoma (MCL)
LENALIDOMIDE SANDOZ is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.